TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06345404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soquelitinib
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soquelitinib matching placebo tablets
Study: NCT05751655

Intervention type: OTHER
Intervention: Prehospital care following drowning accident
Description: Prehospital care provided by the emergency medical service 83 (SAMU 83)
Study: NCT05499663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POSTHOC app
Description: The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
Study: NCT04870775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Program
Description: Mindfulness training program to reduce psychotropathological symptoms in hospital workers
Study: NCT04584866

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endonasal endoscopic pituitary surgery in semi-sitting position
Description: Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endonasal endoscopic pituitary surgery in supine position
Description: Patients will be operated in the standard supine neutral position
Study: NCT06509607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric Lower Limb Training Program
Description: A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Lower Limb Training Program
Description: A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
Study: NCT06527235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasound-guided betamethasone infiltration of the meniscal wall
Description: The perimeniscal injections will be guided by ultrasound with an 18 megahertz (MHz) linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of lidocaine injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall
Description: The perimeniscal injections will be guided by ultrasound with an 18 MHz linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of isotonic saline injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
Study: NCT06522919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell (DC) Vaccine
Description: Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
Study: NCT06201559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole IP 400 mg
Description: Albendazole IP 400 mg tablets will be administered under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Description: Albendazole 400 mg tablets will be administered under fed conditions
Study: NCT05690685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver I Alginate Non-Woven Dressing (Hydro-Alginate)
Description: Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver I Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change up-to six-week follow-up period.
Study: NCT06257875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Matching Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Matching Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: SC Injection
Study: NCT04040296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Action Team Recommendations
Description: Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
Study: NCT05756088

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure the levels of dd-cf DNA
Description: Blood draw to measure the levels of dd-cf DNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure the levels of dd-cf DNA
Description: Blood draw to measure the levels of dd-cf DNA.
Study: NCT05305833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: ATMP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: ATMP
Study: NCT05049213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal spray and 1% PVP- mouthwash and gargle
Description: Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time
Study: NCT06041503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
Study: NCT06106724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphincterotomy
Description: cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: precutting of the papilla by knife needle
Description: precutting of the papilla by knife needle
Study: NCT06041503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
Study: NCT06507748

Intervention type: DEVICE
Group type: OTHER
Intervention: AlgometRx Nociometer
Description: Novel objective pain measurement device
Study: NCT05256225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study: NCT04791748

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular tests
Description: Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
Study: NCT05256225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04791748

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular tests
Description: Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
Study: NCT05256225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04791748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
Study: NCT05256225

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose-Rate Vaginal Cuff Brachytherapy
Description: Undergo vaginal brachytherapy
Study: NCT05188079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: high nitrate supplement
Study: NCT05256225

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose-Rate Vaginal Cuff Brachytherapy
Description: Undergo vaginal brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose-Rate Vaginal Cuff Brachytherapy
Description: Undergo vaginal brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Description: Given SC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT05188079

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: placebo
Study: NCT06174805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Description: Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
Study: NCT06274034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear MUSE S headband

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Participate in meditation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05256225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab/Hyaluronidase-oysk
Description: Given SC
Study: NCT04858334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or CT/MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or CT/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CT/MRI
Study: NCT06325046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Adaptive Radiation Therapy
Description: Undergo near margin-less ART

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04858334

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo CT/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT05652478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide
Description: 25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: 50mg dolutegravir (DTG) one tablet orally once daily for 8 days.
Study: NCT06503159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR) Program
Description: The study intervention is a 9-week MBSR intervention once per week in-person or remotely (via an NIH approved remote platform used in compliance with policy, including HRPP Policy 303). The MBSR will be delivered to groups of 8-12 participants. Only the vaping adolescents will receive MBSR training.
Study: NCT04569591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthrel
Description: Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.
Study: NCT06555562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Stimulation
Description: Ultrasound therapy will be administered to the appropriate target.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active ultrasound stimulation
Description: Non-active ultrasound therapy will be administered to the appropriate target
Study: NCT05652465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)
Description: Device described in protocol
Study: NCT06325046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy
Description: Undergo standard SABR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05418504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental anesthesia
Description: Dental anesthesia, used to do any dental procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental anesthesia
Description: Dental anesthesia, used to do any dental procedure
Study: NCT05694871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Given PO
Study: NCT04269902

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05879484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Phase Ib: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.~Phase II: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Phase Ib: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.~Phase II: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valemetostat
Description: Phase Ib: Valemetostat will be given orally every day of every cycle (DL-1: 100mg, DL1: 150mg, DL2: 200mg).~Phase II: Valemetostat will be given orally daily at the recommended phase 2 dose.
Study: NCT05694871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study: NCT02588807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spirit1
Description: Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
Study: NCT05822713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: 5mg/2ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amisulpride Placebo
Description: 2ml